Ovid Therapeutics (OVID) Retained Earnings (2016 - 2026)

Ovid Therapeutics (OVID) has reported Retained Earnings for 11 consecutive years, with $564.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 50.44% year-over-year to $564.2 million; the trailing twelve-month figure through Jun 2026 stood at $564.2 million (up 50.44% YoY), and the FY2025 full-year result was $452.4 million, up 21.47% from the prior year.
• Retained Earnings improved to $564.2 million in Q2 2026 per OVID's latest filing, from $537.2 million in the prior quarter.
• Across five years, Retained Earnings topped out at $564.2 million in Q2 2026 and bottomed at -$214.0 million in Q3 2022.
• Historically, Retained Earnings has averaged $298.1 million across 5 years, with a median of $368.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings slumped 58.65% in 2022, then surged 291.87% in 2023.
• Over 5 years, Retained Earnings stood at $357.8 million in 2022, then advanced by 2.19% to $365.6 million in 2023, then advanced by 1.89% to $372.5 million in 2024, then climbed by 21.47% to $452.4 million in 2025, then increased by 24.69% to $564.2 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $564.2 million, $537.2 million, and $452.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.